📣 VC round data is live. Check it out!
- Public Comps
- Sight Sciences
Sight Sciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Sight Sciences and similar public comparables like Affluent Medical, Profound Medical, Orchestra BioMed, Stratec and more.
Sight Sciences Overview
About Sight Sciences
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.
Founded
2010
HQ

Employees
216
Website
Financials (LTM)
EV
$193M
Valuation Multiples
Start free trialSight Sciences Financials
Sight Sciences reported last 12-month revenue of $81M and negative EBITDA of ($25M).
In the same LTM period, Sight Sciences generated $70M in gross profit, ($25M) in EBITDA losses, and had net loss of ($39M).
Revenue (LTM)
Sight Sciences P&L
In the most recent fiscal year, Sight Sciences reported revenue of $77M and EBITDA of ($26M).
Sight Sciences is unprofitable as of last fiscal year, with gross margin of 86%, EBITDA margin of (34%), and net margin of (50%).
Financial data powered by Morningstar, Inc.
Sight Sciences Stock Performance
Sight Sciences has current market cap of $236M, and enterprise value of $193M.
Market Cap Evolution
Sight Sciences' stock price is $4.34.
Sight Sciences share price decreased by 10.7% in the last 30 days, and increased by 5.8% in the last year.
Sight Sciences has an EPS (earnings per share) of $-0.71.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $193M | $236M | -4.3% | -10.7% | 15.1% | 5.8% | $-0.71 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSight Sciences Valuation Multiples
Sight Sciences trades at 2.4x EV/Revenue multiple, and (7.8x) EV/EBITDA.
EV / Revenue (LTM)
Sight Sciences Financial Valuation Multiples
As of June 3, 2026, Sight Sciences has market cap of $236M and EV of $193M.
Sight Sciences has a P/E ratio of (6.1x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Sight Sciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Sight Sciences Margins & Growth Rates
Sight Sciences grew revenue by 11% but EBITDA decreased by 15% in the last fiscal year.
In the most recent fiscal year, Sight Sciences reported gross margin of 86%, EBITDA margin of (34%), and net margin of (50%).
Sight Sciences Margins
Sight Sciences Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Sight Sciences Operational KPIs
Sight Sciences' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.5M for the same period.
Sight Sciences' Rule of 40 is (15%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sight Sciences' Rule of X is 2% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Sight Sciences Competitors
Sight Sciences competitors include Affluent Medical, Profound Medical, Orchestra BioMed, Stratec, Dong-A ST, Treace Medical Concepts, Median Technologies, Onward Medical, Carvolix and Eurobio Scientific.
Most Sight Sciences public comparables operate across Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| - | 372.7x | - | (11.9x) | |||
| 12.1x | 9.6x | (5.3x) | (5.8x) | |||
| 4.6x | 7.9x | (3.0x) | (2.2x) | |||
| 1.3x | 1.2x | 9.1x | 8.7x | |||
| 0.8x | 0.8x | 11.0x | 10.4x | |||
| 1.2x | 1.2x | (62.9x) | (53.1x) | |||
| 9.3x | 8.8x | (13.7x) | (13.8x) | |||
| 26.3x | 15.7x | (3.6x) | (2.8x) | |||
This data is available for Pro users. Sign up to see all Sight Sciences competitors and their valuation data. Start Free Trial | ||||||
Sight Sciences VC Funding History
Before going public, Sight Sciences raised $108M in total equity funding, across 6 rounds.
Sight Sciences Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Sight Sciences
| When was Sight Sciences founded? | Sight Sciences was founded in 2010. |
| Where is Sight Sciences headquartered? | Sight Sciences is headquartered in United States. |
| How many employees does Sight Sciences have? | As of today, Sight Sciences has over 216 employees. |
| Who is the CEO of Sight Sciences? | Sight Sciences' CEO is Paul Badawi. |
| Is Sight Sciences publicly listed? | Yes, Sight Sciences is a public company listed on Nasdaq. |
| What is the stock symbol of Sight Sciences? | Sight Sciences trades under SGHT ticker. |
| When did Sight Sciences go public? | Sight Sciences went public in 2021. |
| Who are competitors of Sight Sciences? | Sight Sciences main competitors include Affluent Medical, Profound Medical, Orchestra BioMed, Stratec, Dong-A ST, Treace Medical Concepts, Median Technologies, Onward Medical, Carvolix, Eurobio Scientific. |
| What is the current market cap of Sight Sciences? | Sight Sciences' current market cap is $236M. |
| What is the current revenue of Sight Sciences? | Sight Sciences' last 12 months revenue is $81M. |
| What is the current revenue growth of Sight Sciences? | Sight Sciences revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Sight Sciences? | Current revenue multiple of Sight Sciences is 2.4x. |
| Is Sight Sciences profitable? | No, Sight Sciences is not profitable. |
| What is the current EBITDA of Sight Sciences? | Sight Sciences has negative EBITDA and is not profitable. |
| What is Sight Sciences' EBITDA margin? | Sight Sciences' last 12 months EBITDA margin is (30%). |
| What is the current EV/EBITDA multiple of Sight Sciences? | Current EBITDA multiple of Sight Sciences is (7.8x). |
| How many companies Sight Sciences has acquired to date? | Sight Sciences hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Sight Sciences has invested to date? | Sight Sciences hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Sight Sciences
Lists including Sight Sciences
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.